GENZYME (GENZ) – StreetInsider.com Reports
-
Sanofi (SNY) Says New Data to be Presented at AAN Suggest Positive Effects of Aubagio on Cortical Gray Matter Atrophy
-
Sanofi Genzyme's (SNY) New Investigational Data on Lemtrada Six-Year Efficacy in MS to be Presented at AAN
-
Carl Icahn Liquidates Biogen Idec (BIIB), Chesapeake Energy (CHK); Targets Oshkosh (OSK), Forest Labs (FRX) and Commercial Metals (CMC)
-
Relational Investors Builds New Stakes In PMC-Sierra (PMCS), Assurant (AIZ); Cashes In On Takeovers
-
Global Hunter Securities Starts Aegerion Pharmaceuticals (AEGR) at Buy; Lomitapide – A Potential Best-in-Class Drug
-
Paulson's Paulson & Co Shows New Stakes In Alpha Natural (ANR), Family Dollar (FDO), HP (HP); Raises Transocean (RIG) and Liquidates Pfizer (PFE)
-
Icahn's Icahn Capital Shows New Stake in Amgen (AMGN), Clorox (CLX) and Southern Union (NYSE: SUG); Raises Dynegy (DYN), Lowers Chesapeake (CHK)
-
Global Pharmaceuticals: Global Therapeutic Conference 2011: Focus on Real-World Medicine
-
Relational Investors Builds New Stakes In EA (ERTS), MetLife (MET), Shows Hidden Stakes In Applied Materials (AMAT) and Others
-
Stocks with implied volatility below IV index mean; GENZ MU
-
Stocks with implied volatility below IV index mean; GENZ CEPH
-
After-Hours Movers 03/29: (CEPH) (NLST) (BLK) Higher; (UTA) (ZZ) (VVTV) (ZOOM) Lower
-
BlackRock (BLK) Replacing Genzyme (GENZ) in S&P 500
-
Blackrock (BLK) to replace Genzyme (GENZ) in S&P 500
-
Stocks with implied volatility below 30-day mean; GENZ C AGNC
-
Stocks with implied volatility below 30-day mean; GENZ MGM DRYS
-
Canaccord Genuity Morning Coffee on Merck & Co. (MRK) and Sanofi-Aventis (SNY): So Long, Farewell, Au Revoir
-
Stocks with implied volatility below 30-day mean; PFE C GENZ
-
Stocks with implied volatility below 30-day mean; AVNR C
-
Genzyme (GENZ) Board Unanimously Recommends Shareholders Approves Sanofi-Aventis (SNY)
-
Stocks with implied volatility below 30-day mean; C S GENZ
-
Genzyme (GENZ) Completes Pharma Intermediates Sale
-
Top 10 News Items 2/14-2/18: NYSE Euronext/Deutsche Boerse Announces Definitive Agreement, Sanofi, Genzyme Finally Approve Deal, Stocks Continue Higher, Up 28% Since Sept.
-
Jefferies Cuts Estimate & Raises Price Target on BioMarin Pharmaceutical (BMRN), Maintains Buy Rating
-
Canaccord Genuity Morning Coffee on Sanofi-Aventis (SNY) and Genzyme (GENZ): An Extra $5 Will Help The Medicine Go Down
-
Jefferies Downgrades Genzyme (GENZ) to Hold, Lowers EPS Estimates For FY11 & FY12
-
Morgan Joseph Downgrades Genzyme (GENZ) to Hold; To be Acquired for $74 Plus CVRs
-
Notable ETF Movers of the Day 02/16: (XRT) (USO) (TAN) Higher; (UNG) (VXX) (UUP) Lower
-
Cowen Downgrades Genzyme (GENZ) to Neutral
-
Notable Mergers and Acquisitions of the Day 02/16: GENZ/SNY, BEE, ARG/APD
-
Pre-Open Movers 2/16: (FDO) (VCLK) (DELL) Higher; (TNGN) (DSCO) (OMX) Lower
-
Genzyme Corp. (GENZ) Misses Q4 Views
-
Genzyme (GENZ) Agrees To Be Acquired by Sanofi-aventis (SNY) for $20.1 Billion
-
Trading Radar for 02/16: NVIDIA (NVDA), Deere (DE), Genzyme (GENZ), CBS Corp. (CBS), NetApp (NTAP) Report
-
Paulson's Paulson & Co. Reduces Citi (C) Exposure; Keeps Gold Level; Likes Tech (STX)(RIG)ABX)(JPM)
-
Genzyme (GENZ) Reportedly Acquired by Sanofi-Aventis for $19.2B
-
Genzyme (GENZ) Jumps On Reports Deal Reached at $74/Share Plus Rights
-
Genzyme Corp. (GENZ) sees upside on news Sanofi-Aventis (SNY) deal could be announced soon
-
Cohen's SAC Capital Shows Raised Stakes in Apple (AAPL), Microsoft (MSFT), Gap (GPS), DirecTV (DTV), Genzyme (GENZ)
-
Stocks with implied volatility above mean; ARG GENZ VLO
-
Icahn Discloses 5.06% Passive Stake in Genzyme (GENZ)
-
Stocks with implied volatility above mean; ARG GENZ TIVO
-
Goldman Sachs (GS) Has 6.8% Stake in Genzyme (GENZ, SNY)
-
Notable Mergers and Acquisitions of the Day 02/10: CNET, VRX/GENZ, ECA/PTR
-
Valeant (VRX) Acquires Canadian Rights to Cholestagel from Genzyme (GENZ)
-
Stocks with implied volatility above mean; CSCO GENZ AKAM
-
Genzyme (GENZ) Stock Volatile With Pushing and Pulling In Sanofi Deal
-
Genzyme (GENZ) Valued at $20B by Sanofi Aventis; Deal Could Happen Within a Week
-
Genzyme (GENZ) Dips On Sanofi Headlines
-
Sanofi (SNY) talks said to value Genzyme (GENZ) at $76-$77/share with CVR fee -Bloomberg
Back to GENZ Stock Lookup